^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KPG-121

    i
    Other names: KPG-121, KPG121, KPG 121
    Associations

    News

    Trials
    Company:
    Kangpu Biopharma
    Drug class:
    CRL4-CRBN E3 ubiquitin ligase modulator
    Related drugs:
    Associations

    News

    Trials
    over1year
    Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients (clinicaltrials.gov)
    P1, N=16, Completed, Kangpu Biopharmaceuticals, Ltd. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • KPG-121
    over4years
    [VIRTUAL] KPG-121, a novel CRBN modulator, potently inhibits growth of metastatic castration resistant prostate cancer as a single agent or in combination with androgen receptor signaling inhibitors both in vitro and in vivo (AACR-II 2020)
    KPG-121 is a novel generation of Lenalidomide analogue. Results from in vivo metastatic castration resistant prostate cancer xenograft models demonstrated that KPG-121 at tested daily dose levels ranging from 1.0 mg/kg to 10 mg/kg in combination with Enzalutamide, Abiraterone Acetate, Apalutamide or Darolutamide significantly improved anti-tumor efficacy compared to the AR signaling inhibitors alone. In addition, KPG-121 showed favorable DMPK profiles and potentially manageable toxicity in pre-clinical IND enabling study.
    Preclinical • Combination therapy
    |
    CRBN (Cereblon)
    |
    lenalidomide • Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • Erleada (apalutamide) • KPG-121